Amgen releases drug trial results
From Times Staff and Wire Reports
Amgen Inc. said its experimental osteoporosis drug denosumab reduced fractures in women with the bone-thinning disease in a study.
The trial of 7,800 women with osteoporosis found that denosumab strengthened bones and reduced spinal and hip fractures, the Thousand Oaks-based company said.
